Aphria Inc (TSX:APHA) (NYSE:APHA) announced Friday that it has completed its first transfer of plant cuttings from four of its cannabis strains to Denmark-based Schroll Medical as part of the two companies’ strategic partnership.
The shipment was completed under an export permit from Health Canada, an import permit from the Danish Medicines Agency and a phytosanitary certificate from the Canadian Food Inspection Agency.
“We are pleased to introduce the first four Aphria strains to be produced in Europe, through our strategic alliance with Schroll,” said Hendrik Knopp, managing director of Aphria Germany. “This marks another important milestone for Aphria as we extend our leadership position in the European market.”
Aphria oversees the distribution of medical cannabis produced by the partnership, which is expected to be sold in markets across Europe. The Leamington, Ontario-based cannabis company plans to complete a second shipment of additional strains to Schroll in the coming months.
Aphria shares added 1.83% to $8.90 in pre-market trading in New York on Friday.
Contact Ellen Kelleher at [email protected]